Amendments to the Specification:

The paragraph beginning at page 1, line 9 has been amended to read as follows:

This application is a divisional of U.S. Patent Application No. 09/859,053, filed May 16, 2001, which claims priority from Japanese Application No. 2000-147116, filed May 18, 2000, and Japanese Application No. 2001-99598, Filed March 30, 2001. The prior applications are incorporated herein by reference in their entirety.

The paragraph beginning at page 4, line 8 has been amended to read as follows:

The ligands for CD28 and CTLA-4 are CD80 (B7-1) and CD86 (B7-2) in human and mice. CTLA-4 has about 20 times as high affinity to both ligands as CD28. It has been elucidated that the amino acid sequence structures "MYPPPY (Met-Tyr-Pro-Pro-Pro-Tyr; SEQ ID NO:41)" conserved through animal species is important for the binding of CD28 and CTLA-4 to CD80 (B7-1). It has also been reported that, when CD28 is stimulated, PI3 kinase (phosphoinositide 3 kinase, PI3K) associates with the phosphorylated tyrosine residue in a partial sequence "YMNM (Tyr-Met-Asn-Met; SEQ ID NO:42)" of CD28 and that CD28 plays an important role in intracellular signal transmission through this "YxxM" structure. Furthermore, it has been reported that CTLA-4 also has a sequence represented by "YxxM," namely "YVKM (Tyr-Val-Lys-Met; SEQ ID NO:43)" in its cytoplasmic region and that, after being stimulated, SYP associates with this sequence.

The paragraph beginning at page 28, line 29 has been amended to read as follows:

Figs. 1A-1L show ~~Fig. 1 shows~~ respective reactivities of anti-human IgG antibody, anti-human Igκ antibody and anti-human IgFc antibody to the human anti-human AILIM monoclonal antibody, analyzed by cell ELISA using a flow cytometer.

The paragraph beginning at page 29 line 2 has been amended to read as follows:

Fig. 1A shows the ~~Panel (a):~~ result of an assay in which biotin-labeled anti-human IgG antibody as a secondary antibody was added in the absence of primary antibody into the microplate where wild-type HPB-ALL cells had been plated.

The paragraph beginning at page 29, line 5 has been amended to read as follows:

Fig. 1B shows the ~~Panel (b):~~ result of an assay in which biotin-labeled anti-human Igκ antibody as a secondary antibody was added in the absence of primary antibody into the microplate where wild-type HPB-ALL cells had been plated.

The paragraph beginning at page 29, line 8 has been amended to read as follows:

Fig. 1C shows the ~~Panel (c):~~ result of an assay in which biotin-labeled anti-human IgFc antibody as a secondary antibody was added in the absence of primary antibody into the microplate where wild-type HPB-ALL cells had been plated.

The paragraph beginning at page 29, line 11 has been amended to read as follows:

Fig. 1D shows the ~~Panel (d):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-136 was used as a primary antibody and biotin-labeled anti-human IgG antibody was used as a secondary antibody.

The paragraph beginning at page 29, line 14 has been amended to read as follows:

Fig. 1E shows the ~~Panel (e):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-136 was used as a primary antibody and biotin-labeled anti-human Igκ antibody was used as a secondary antibody.

The paragraph beginning at page 29, line 17 has been amended to read as follows:

Fig. 1F shows the ~~Panel (f):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-136 was used as a primary antibody and biotin-labeled anti-human IgFc antibody was used as a secondary antibody.

The paragraph beginning at page 29, line 20 has been amended to read as follows:

Fig. 1G shows the ~~Panel (g):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-138 was used as a primary antibody and biotin-labeled anti-human IgG antibody was used as a secondary antibody.

The paragraph beginning at page 29, line 23 has been amended to read as follows:

Fig. 1H shows the ~~Panel (h):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-138 was used as a primary antibody and biotin-labeled anti-human Igκ antibody was used as a secondary antibody.

The paragraph beginning at page 29, line 26 has been amended to read as follows:

Fig. 1I shows the ~~Panel (i):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-138 was used as a primary antibody and biotin-labeled anti-human IgFc antibody was used as a secondary antibody.

The paragraph beginning at page 29, line 29 has been amended to read as follows:

Fig. 1J shows the ~~Panel (j):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-139 was used as a primary antibody and biotin-labeled anti-human IgG antibody was used as a secondary antibody.

The paragraph beginning at page 30, line 1 has been amended to read as follows:

Fig. 1K shows the ~~Panel (k):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-139 was used as a primary antibody and biotin-labeled anti-human Igκ antibody was used as a secondary antibody.

The paragraph beginning at page 30, line 4 has been amended to read as follows:

Fig. 1L shows the ~~Panel (l):~~ result of an assay in which human anti-human AILIM monoclonal antibody JMab-139 was used as a primary antibody and biotin-labeled anti-human IgFc antibody was used as a secondary antibody.

The paragraph beginning at page 127, line 21 has been amended to read as follows:

Amino acid sequence: SEQ ID NO:28 (comprising signal sequence: amino acid number 1 to 19, variable region: amino acid number 20 to 117 ~~118~~)